Each summer, the American Society for Clinical Oncology holds the world’s largest conference for cancer researchers, doctors and other medical professionals. Results from clinical trials and other studies are released, which give scientists a fresh look at treatments that may or may not hold great promise in the march toward a cure for cancer.
Dr. Axel Grothey of the Mayo Clinic will explain what science is now telling us about colorectal cancer and how it may impact your treatment in the near future.
Each summer, the American Society for Clinical Oncology holds the world’s largest conference for cancer researchers, doctors and other medical professionals. Results from clinical trials and other studies are released, which give scientists a fresh look at treatments that may or may not hold great promise in the march toward a cure for cancer.
Dr. Axel Grothey of the Mayo Clinic will explain what science is now telling us about colorectal cancer and how it may impact your treatment in the near future.
Fight Colorectal Cancer’s Medical Advisory Board Member, Axel Grothey, MD, focused this webinar to stage III colon cancer patients. Dr. Grothey, medical oncologist at Mayo Clinic, will spend the hour discussing current treatment options and exciting new research that pertains to stage III colon cancer patients.
This downloadable slidedeck, presented in a regional grand rounds series, focuses on increasing awareness about current and emerging treatment options for patients with newly diagnosed and recurrent ovarian cancer.
Fight Colorectal Cancer’s Medical Advisory Board Member, Axel Grothey, MD, focused this webinar to stage III colon cancer patients. Dr. Grothey, medical oncologist at Mayo Clinic, will spend the hour discussing current treatment options and exciting new research that pertains to stage III colon cancer patients.
This downloadable slidedeck, presented in a regional grand rounds series, focuses on increasing awareness about current and emerging treatment options for patients with newly diagnosed and recurrent ovarian cancer.
16. National Cancer Center
1. 悪性腫瘍に起因した難治性腹水。
2. 穿刺排液以外の方法で症状改善が得られない。
3. Palliative Prognostic Index (P.P.I)<6
4. 文書による同意
臓器機能の規定なし
症例選択規準(抜粋)
難治性腹水に対するシャント治療の有効性を評価する
ランダム化比較試験(JIVROSG-0803)
28. Phase II/III trial of catumaxomab
for malignant ascites
Int. J. Cancer: 127, 2209–2221, 2010
Puncture-free survival Overall survival
Median 11 days vs. 46 days
P < 0.0001
Median 68 days vs. 72 days
P = 0.085
29. Phase II/III trial of catumaxomab
for malignant ascites
Int. J. Cancer: 127, 2209–2221, 2010
副作用
catumaxomab
control
*P < 0.05